Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.
Read Full NewsALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Why patients with IgA nephropathy want to understand their disease, not just follow instructions.
Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.
Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.
Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.
1.
UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts
2.
Chronic pain and poor sleep are troublesome bed partners.
3.
Saturated Fat Tied to Worse Survival After Prostate Cancer
4.
Guidelines for patient training and radiation protection for patients treated with radioactive iodine for thyroid cancer
5.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
1.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
2.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
3.
Exposure Modeling for Bispecific Antibodies: Scientific Foundations and Clinical Implications
4.
Risk Assessment of Treatment-Related Liver Injury in Cancer Care
5.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge